Optimi Health introduces standardised microdose psilocybin capsules for clinical research

Lilly acquires 4E Therapeutics to advance non-opioid chronic pain treatment

AlzeCure reports positive Phase Ib results for Alzheimer's candidate ACD856

Minghui Pharmaceutical presents MHB018A Phase I/II results for thyroid eye disease at ENDO 2026

Kalohexis presents dual MC3R/MC4R activation data at ENDO 2026

Hillhurst Bio reports first subject dosed in Phase 2a trial of HBI-002 for Parkinson's disease

Lonza and Antharis Therapeutics enter target-specific licence agreement

Halia Therapeutics' ofirnoflast granted FDA Fast Track designation for lower-risk myelodysplastic syndromes

Inhibrx's ozekibart BLA accepted by FDA for chondrosarcoma treatment

Sensei Biotherapeutics changes name to Faeth Therapeutics

Bayer receives FDA approval for AMBELVIST MRI contrast agent

Johnson & Johnson commits over USD1bn to expand Vision manufacturing in Jacksonville

Genmab reports strong epcoritamab results in elderly newly diagnosed DLBCL patients

AstraZeneca secures US approval for Truqap combination in PTEN‑deficient prostate cancer

Acousia Therapeutics reports positive top-line efficacy results for ACOU085 in cisplatin-induced ototoxicity